480 related articles for article (PubMed ID: 22357831)
21. Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.
Kuhlmann A; von der Schulenburg JG
Eur J Health Econ; 2017 Apr; 18(3):273-292. PubMed ID: 26905404
[TBL] [Abstract][Full Text] [Related]
22. Economic evaluation of second generation pneumococcal conjugate vaccines in Norway.
Robberstad B; Frostad CR; Akselsen PE; Kværner KJ; Berstad AK
Vaccine; 2011 Nov; 29(47):8564-74. PubMed ID: 21945264
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older Populations.
Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
J Am Geriatr Soc; 2020 Jun; 68(6):1271-1278. PubMed ID: 32086950
[TBL] [Abstract][Full Text] [Related]
24. A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult.
Ngamprasertchai T; Kositamongkol C; Lawpoolsri S; Rattanaumpawan P; Luvira V; Chongtrakool P; Kaewkungwal J; Chokephaibulkit K; Phisalprapa P
Front Public Health; 2023; 11():1071117. PubMed ID: 37457251
[TBL] [Abstract][Full Text] [Related]
25. The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults.
Feldman C; Dlamini SK; Madhi SA; Meiring S; von Gottberg A; de Beer JC; de Necker M; Stander MP
PLoS One; 2020; 15(1):e0227945. PubMed ID: 31995597
[TBL] [Abstract][Full Text] [Related]
26. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan.
Shinjoh M; Togo K; Hayamizu T; Yonemoto N; Morii J; Perdrizet J; Kamei K
Expert Rev Vaccines; 2024; 23(1):485-497. PubMed ID: 38682661
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
Dirmesropian S; Wood JG; MacIntyre CR; Beutels P; McIntyre P; Menzies R; Reyes JF; Chen C; Newall AT
Vaccine; 2017 Aug; 35(34):4307-4314. PubMed ID: 28693751
[TBL] [Abstract][Full Text] [Related]
29. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
Jackson LA; Gurtman A; van Cleeff M; Frenck RW; Treanor J; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3594-602. PubMed ID: 23688525
[TBL] [Abstract][Full Text] [Related]
30. Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context?
Kulpeng W; Leelahavarong P; Rattanavipapong W; Sornsrivichai V; Baggett HC; Meeyai A; Punpanich W; Teerawattananon Y
Vaccine; 2013 Jun; 31(26):2839-47. PubMed ID: 23588084
[TBL] [Abstract][Full Text] [Related]
31. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.
Boccalini S; Bechini A; Levi M; Tiscione E; Gasparini R; Bonanni P
Hum Vaccin Immunother; 2013 Mar; 9(3):699-706. PubMed ID: 23295824
[TBL] [Abstract][Full Text] [Related]
33. Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016.
Vila-Corcoles A; Hospital I; Ochoa-Gondar O; Satue E; de Diego C; Vila-Rovira A; Gómez-Bertomeu F; Raga X; Aragón M
Vaccine; 2020 Jan; 38(5):1170-1180. PubMed ID: 31759735
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
35. Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations.
Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
Am J Prev Med; 2020 Apr; 58(4):487-495. PubMed ID: 32001052
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness of Pneumococcal Vaccines for Adults Aged 65 Years and Older in Argentina.
Giglio ND; Castellano VE; Mizrahi P; Micone PV
Value Health Reg Issues; 2022 Mar; 28():76-81. PubMed ID: 34801962
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia.
Sundaram N; Chen C; Yoong J; Luvsan ME; Fox K; Sarankhuu A; La Vincente S; Jit M
Vaccine; 2017 Feb; 35(7):1055-1063. PubMed ID: 28109706
[TBL] [Abstract][Full Text] [Related]
38. Evaluating the cost-effectiveness of a sequential pneumococcal vaccination compared to single-dose vaccination strategy for adults in Hong Kong.
Shami JJP; Pathadka S; Chan EW; Hui J; Sato R; Patil S; Li X
Hum Vaccin Immunother; 2020 Aug; 16(8):1937-1944. PubMed ID: 31977268
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
[TBL] [Abstract][Full Text] [Related]
40. Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.
Chen C; Beutels P; Wood J; Menzies R; MacIntyre CR; McIntyre P; Newall AT
Vaccine; 2018 Oct; 36(42):6307-6313. PubMed ID: 30213457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
